Company Filing History:

13 out of 4,770

Merck + Co., Inc.

Years Active: 1993-2007

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7176310 - Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents (2007-02-13),

2. 6358970 - Integrin receptor antagonists (2002-03-19),

3. 5952306 - Integrin receptor antagonists (1999-09-14),

4. 5929120 - Guainidino, formamidino, amino and related compounds for inhibiting (1999-07-27),

5. 5919792 - Integrin antagonists (1999-07-06),

6. 5854245 - Fibrinogen receptor antagonists (1998-12-29),

7. 5852045 - Fibrinogen receptor antagonists (1998-12-22),

8. 5741796 - Pyridyl and naphthyridyl compounds for inhibiting osteoclast-mediated (1998-04-21),

9. 5648368 - Fibrinogen receptor antagonists (1997-07-15),

10. 5455243 - Fibrinogen receptor antagonists for inhibiting aggregation of blood (1995-10-03),

11. 5397791 - Fibrinogen receptor antagonists (1995-03-14),

12. 5321034 - Fibrinogen receptor antagonists (1994-06-14),

13. 5281585 - Fibrinogen receptor antagonists for inhibiting aggregation of blood (1994-01-25),

14. 5264420 - Fibrinogen receptor antagonists (1993-11-23),

Title: Nathan C Ihle: Innovator in Pharmaceutical Chemistry

Introduction

Nathan C Ihle is a prominent inventor based in Mercer Island, WA (US), known for his significant contributions to pharmaceutical chemistry. With a total of 14 patents to his name, he has made remarkable advancements in the field of anti-inflammatory agents and integrin receptor antagonists.

Latest Patents

Among his latest patents, Ihle has developed pyrimidinecarboxamide derivatives that serve as anti-inflammatory agents. This invention focuses on compounds that are effective in treating inflammatory disorders in mammals. Additionally, he has worked on integrin receptor antagonists, which are crucial for inhibiting bone resorption and treating various conditions such as osteoporosis, diabetic retinopathy, and cancer.

Career Highlights

Throughout his career, Nathan C Ihle has been associated with notable companies, including Merck & Company, Inc. and UCB S.A. His work in these organizations has allowed him to contribute to groundbreaking research and development in the pharmaceutical industry.

Collaborations

Ihle has collaborated with esteemed colleagues such as George D Hartman and Mark E Duggan, further enhancing the impact of his inventions in the scientific community.

Conclusion

Nathan C Ihle's innovative work in pharmaceutical chemistry has led to significant advancements in the treatment of inflammatory disorders and other medical conditions. His contributions continue to influence the field and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com